18:50 , May 4, 2018 |  BC Week In Review  |  Clinical News

Incyte 'downsizing' IDO1 program, ends some combo trials

Incyte Corp. (NASDAQ:INCY) said it is "downsizing" its program evaluating epacadostat, its indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. The company plans to halt enrollment of six pivotal trials of epacadostat in combination with anti-PD-1 mAbs Keytruda...
15:36 , May 4, 2018 |  BC Week In Review  |  Clinical News

BMS discontinues pair of IDO1, Opdivo combo trials

Bristol-Myers Squibb Co. (NYSE:BMY) discontinued two Phase III trials evaluating indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor BMS-986205 in combination with its PD-1 inhibitor Opdivo nivolumab, according to ClinicalTrials.gov. According to the website, the company cited that...
20:55 , May 1, 2018 |  BC Extra  |  Company News

Incyte 'downsizing' IDO1 program, ends some combo trials

Incyte Corp. (NASDAQ:INCY) reported 1Q18 earnings and said it is "downsizing" its program evaluating epacadostat, its indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. The company plans to halt enrollment of six pivotal trials of epacadostat in combination...
20:52 , Apr 30, 2018 |  BC Extra  |  Clinical News

BMS discontinues pair of IDO1, Opdivo combo trials

Bristol-Myers Squibb Co. (NYSE:BMY) discontinued two Phase III trials evaluating indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor BMS-986205 in combination with its PD-1 inhibitor Opdivo nivolumab, according to ClinicalTrials.gov. According to the website, the company cited that...
23:45 , Apr 20, 2018 |  BioCentury  |  Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
21:25 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

BMS reports response data from Phase I/IIa trial of IDO1 inhibitor/Opdivo combo

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from the dose-expansion portion of the Phase I/IIa CA017-003 trial showing that oral BMS-986205 plus IV Opdivo nivolumab led to an objective response rate (ORR) of 32% and a...
00:47 , Apr 12, 2017 |  BC Week In Review  |  Clinical News

BMS-986205: Ph I/IIa data

Data from 42 evaluable patients with advanced malignant tumors in an open-label, dose-escalation, international Phase I/IIa trial showed that once-daily 25-200 mg oral BMS-986205 for 2 weeks followed by BMS-986205 in combination with Opdivo nivolumab...
22:45 , Apr 7, 2017 |  BioCentury  |  Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
07:00 , May 2, 2016 |  BioCentury  |  Finance

Flexus redux

Venture backers of Flexus Biosciences Inc. are back for round two with spinout FLX Bio Inc. This time, the goal is to develop the cancer company's assets much further before entertaining M&A offers. Last week,...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Company News

Flexus Biosciences, Bristol-Myers deal

Bristol-Myers will acquire Flexus for $800 million up front and up to $450 million in development milestones. The companies said the deal will close this quarter. Flexus’ F001287, a small molecule inhibitor of ...